The Super Bowl is once again getting the GLP-1 ad treatment.

Hims & Hers is back with another combative spot that calls out the disparities in healthcare experiences between the …

Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.

One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.

What drug ads will air during Sunday’s Super Bowl? STATus Report host Alex Hogan and reporter at large Damian Garde have a rundown of what to expect.

Semaglutide, the active ingredient in the weight-loss medications Ozempic and Wegovy, offers substantial cardiovascular benefits for selected patients without diabetes who have established heart disease, but further price reductions are needed to make the therapy good value for money, according to a new analysis from researchers at Beth Israel Deaconess Medical Center (BIDMC).

In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

(MedPage Today) — Clinicians are seeing more cases of “agonorexia,” when use of GLP-1 receptor agonists turns into disordered eating. (New York Post)
Colorado could become the first state to use ibogaine, a plant-based psychoactive compound…

Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.

Novo Nordisk said Wednesday that demand for its Wegovy pill got off to a strong start after it launched in the U.S. in early January

Popular weight-loss drugs like Ozempic and Wegovy can dramatically curb appetite, but experts warn many users are flying blind when it comes to nutrition. New research suggests people taking these medications may not be getting enough guidance on protein, vitamins, and overall diet quality, increasing the risk of muscle loss and nutrient deficiencies.

Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.

Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.

Semaglutide erased the constant mental chatter about food that had ruled her life, but along with it went her awareness of basic needs.

Writer Kristen Reed shares her weight loss journey with compounded semaglutide. Photography courtesy of Kristen Reed

Health and wellness touch everyone’s life differently. This is one person’s story. The views and opinions expressed are those of the speaker and do not necessarily reflect the views or positions of Healthline Media.

The Food and Drug Administration (FDA) recently approved a tablet version of the GLP-1 drug Wegovy for weight loss. Image courtesy of Novo Nordisk

Novo Nordisk officials said a new pill version of its weight loss drug Wegovy is now available in the United States.

The Food and Drug Administration recently approved the Wegovy tablet as a prescription treatment for obesity and weight management. 

Research shows that people who stop taking GLP-1 medications regain weight within 2 years. Image Credit: Tatsiana Volkava/Getty Images

A new study has found that people regain weight within 2 years of stopping a GLP-1 drug.

Metabolic improvements also tend to fade within that time, researchers found.

Experts advise that slowly tapering off the medication is better than quitting abruptly.

A combination of hormone therapy and the GLP-1 drug tirzepatide may promote weight loss in postmenopausal females. Image Credit: Mauro Grigollo/Stocksy

A new study found that postmenopausal females who use hormone therapy in combination with tirzepatide experience greater weight loss compared to those who don’t. 

Tirzepatide (Zepbound) is an FDA-approved medication prescribed for weight loss. It’s also the active ingredient in the GLP-1 medication Mounjaro to treat type 2 diabetes.

Emerging evidence suggests that oral semaglutide may reduce the risk of heart failure–related events in people with type 2 diabetes. JasonDoiy/Getty Images

Oral semaglutide may reduce heart failure events in high-risk individuals with type 2 diabetes.

The benefit appeared strongest among those with a common but hard-to-treat form of heart failure. 

Type 2 diabetes and heart disease often co-occur and the findings could pave the way for new treatments.

Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.

Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders.

(MedPage Today) — More lawsuits are alleging that patients are not being sufficiently warned of certain severe injuries associated with GLP-1 receptor agonists. (USA Today)
Meanwhile, the U.K.’s Medicines and Healthcare Products Regulatory Agency…

In the world of obesity research, the arrival of GLP-1 drugs like Ozempic feels seismic. At a recent conference, Martin Binks, a leader in obesity research, found himself marveling with a colleague: “Can you believe we finally reached this moment, that we lived long enough to see this?”

NEW YORK–(BUSINESS WIRE) February 03, 2026 — Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1…

Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.

Sciwind Biosciences Co. Ltd. said Jan. 30 it won Chinese approval for self-developed glucagon-like peptide-1 (GLP-1) receptor agonist, ecnoglutide (Xianyida), to treat adults with type 2 diabetes.

Nearly three months after winning a contentious bid to buy obesity drugmaker Metsera Inc. for $10 billion, Pfizer Inc. reported its first statistically significant top-line data of the acquired lead, ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, showing a mean placebo-adjusted weight loss of up to 12.3% at 28 weeks, as well as competitive tolerability.

Researchers at Steno Diabetes Center Copenhagen reported that starting a GLP-1 receptor agonist (GLP-1RA) coincided with slightly healthier supermarket purchases. Grocery purchases from GLP-1RA users in Denmark contained modestly fewer calories and sugars and slightly more protein per 100 g of food after treatment began than before.

TUESDAY, Feb. 3, 2026 — Postmenopausal women who used hormone therapy lost significantly more weight while taking tirzepatide than women only taking tirzepatide, according to a study published online Jan. 22 in The Lancet Obstetrics, Gynaecology…

While CagriSema bested Novo Nordisk’s Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma’s 25% weight loss goal.

(MedPage Today) — Oral semaglutide (Rybelsus) protected against heart failure events in type 2 diabetes patients with a history of heart failure and either atherosclerotic cardiovascular disease, chronic kidney disease, or both, according to findings…

(MedPage Today) — Note that some links may require registration or subscription.
The United Kingdom’s Medicines and Healthcare Products Regulatory Agency strengthened its warnings on GLP-1 receptor agonists and dual GLP-1/GIP agonists to include…

(MedPage Today) — GLP-1 receptor agonist use was tied to a lower risk of recurrent major adverse limb events (MALEs) in people with diabetes compared with another drug class, a retrospective Taiwanese study showed.
Among 17,288 patients, new…

A renowned physician-scientist says treatment is not one-size-fits-all.

THURSDAY, Jan. 29, 2026 — Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with reduced postoperative revision following functional endoscopic sinus surgery (FESS) for up to five years among patients with chronic…

(MedPage Today) — Note that some links may require registration or subscription.
“Night owls” may be at higher risk of cardiovascular disease, but it mostly comes down to their overall health behaviors, according to a U.K. Biobank cohort study…

(MedPage Today) — Use of tirzepatide (Mounjaro, Zepbound) was tied to a reduced incidence of new or progressive diabetic retinopathy and fewer complications in patients with diabetes and overweight/obesity, a retrospective study suggested.
In…